List of Excipients in Branded Drug ZIIHERA

« Back to Dashboard

Ziihera Excipient Strategy and Commercial Opportunities in Zanidatamab Drug Development

Last updated: September 5, 2026

Ziihera, the brand name for zanidatamab-hrii, is a HER2-targeted bispecific antibody approved by the FDA for previously treated, unresectable locally advanced or metastatic HER2-positive biliary tract cancer. Its current formulation is a lyophilized intravenous product using histidine buffer, sucrose, and polysorbate 20. The principal excipient opportunities are long-term biologic stability, lower-cost manufacturing, ready-to-use delivery, subcutaneous conversion, and differentiated presentation protection.[1]

What is Ziihera and how is it regulated?

Ziihera is a bispecific antibody that binds two non-overlapping epitopes of HER2. The dual binding mechanism is designed to promote receptor clustering, internalization, antibody-dependent cellular cytotoxicity, and other antitumor effects.

The FDA granted accelerated approval on November 20, 2024, for adults with previously treated, unresectable locally advanced or metastatic HER2-positive biliary tract cancer, as determined by an FDA-approved test.[2] The approved regimen is 20 mg/kg by intravenous infusion every two weeks until disease progression or unacceptable toxicity.[1]

Regulatory item	Ziihera status
Active ingredient	Zanidatamab-hrii
Product type	Bispecific monoclonal antibody
Sponsor and manufacturer	Jazz Pharmaceuticals, following its acquisition of Kazia-related rights from BeiGene in the zanidatamab transaction structure
FDA approval	November 20, 2024
Approval pathway	Accelerated approval
Initial indication	Previously treated, unresectable locally advanced or metastatic HER2-positive biliary tract cancer
Dosage form	Lyophilized powder for intravenous infusion
Strength	300 mg single-dose vial
Dose	20 mg/kg every two weeks
Regulatory reference	Biologics License Application
Orange Book status	Not listed as a small-molecule drug; biologic patent information is addressed through the Purple Book and related patent-disclosure processes

The accelerated approval is based on response data from Study 101 and requires confirmatory evidence of clinical benefit. The confirmatory HERIZON-BTC-302 study is intended to establish benefit in first-line HER2-positive biliary tract cancer.[2,3]

What excipients are used in the Ziihera formulation?

The commercial Ziihera vial contains zanidatamab-hrii with histidine, histidine hydrochloride monohydrate, sucrose, and polysorbate 20. The product is reconstituted with sterile water for injection and diluted in an appropriate intravenous solution before administration.[1]

Excipient or presentation element	Functional role	Commercial relevance
Histidine	Primary buffering system	Controls pH and supports protein stability during storage
Histidine hydrochloride monohydrate	Counterion and buffer component	Establishes buffer capacity and target formulation pH
Sucrose	Tonicity agent and lyoprotectant	Protects the antibody during freezing and drying
Polysorbate 20	Surfactant	Reduces interfacial adsorption and agitation-related aggregation
Lyophilized cake	Solid-state presentation	Supports storage stability and global distribution
Sterile water for injection	Reconstitution diluent	Converts the powder to an injectable solution
Intravenous infusion solution	Administration vehicle	Permits weight-based dosing and hospital administration

The formulation is consistent with a conventional high-value antibody strategy: use a relatively simple excipient system, avoid unnecessary formulation complexity, and manufacture a stable lyophilized drug product that can tolerate international shipping and hospital reconstitution.

Why does Ziihera use a lyophilized formulation?

Lyophilization can improve the physical and chemical stability of a sensitive antibody compared with a liquid formulation. The approach reduces the risk of degradation caused by hydrolysis, agitation, temperature variation, and prolonged storage in the liquid state.

For Ziihera, the lyophilized format has several commercial advantages:

1. It supports a two-year refrigerated shelf-life target if validated by stability data.
2. It reduces dependence on continuous liquid-state stability during distribution.
3. It accommodates a concentrated antibody dose in a standard vial.
4. It can simplify global cold-chain management.
5. It creates a distinct drug-product platform that may be protectable through formulation, lyophilization-cycle, container-closure, and reconstitution claims.

The principal trade-off is operational. Hospitals must reconstitute the vial, calculate the weight-based dose, withdraw the appropriate volume, and administer the product by infusion. Each step creates opportunities for dosing error, product loss, preparation delay, and nursing labor.

What excipient strategy supports Ziihera lifecycle management?

The current excipient system provides a solid commercial baseline, but the highest-value lifecycle opportunities are likely to involve delivery and manufacturing rather than a simple substitution of one buffer or sugar.

Maintain the current low-complexity platform

Histidine, sucrose, and polysorbate 20 are widely understood by regulators and contract manufacturers. Maintaining this system can reduce comparability risk and support technology transfer between manufacturing sites.

This strategy is useful for expansion into additional indications, where clinical supply must scale quickly. A formulation change during an indication expansion can create bridging requirements, additional stability work, and manufacturing comparability obligations.

Develop a polysorbate-reduced or polysorbate-free version

Polysorbate 20 can undergo oxidation and hydrolysis, generating degradation products that may contribute to protein aggregation or particle formation. A second-generation formulation could evaluate:

• Polysorbate 80;
• poloxamers;
• nonionic surfactant combinations;
• sucrose or trehalose systems with lower surfactant concentration;
• amino-acid or sugar-based stabilizer systems.

A successful polysorbate-reduced formulation could improve impurity control and extend shelf life. The commercial value would depend on demonstrated superiority, because a formulation change that only replaces one accepted surfactant may not justify additional manufacturing complexity.

Optimize the lyophilization cycle

The lyophilization cycle can affect cake structure, residual moisture, reconstitution time, aggregation, and vial-to-vial consistency. Intellectual-property opportunities may arise from:

• controlled freezing rates;
• annealing conditions;
• primary-drying pressure;
• secondary-drying temperature;
• residual-moisture targets;
• reconstitution time;
• agitation tolerance after reconstitution.

These claims can be more difficult to design around when they depend on broad process conditions. They become more commercially valuable when they produce measurable advantages such as shorter reconstitution, lower aggregation, higher recovery, or improved stability at elevated temperature.

Evaluate a liquid formulation

A room-temperature or refrigerated liquid version would remove the reconstitution step and may improve hospital workflow. The main technical risks are aggregation, particle formation, viscosity, surfactant degradation, and loss of potency over time.

A liquid formulation could support:

• prefilled infusion bags;
• pharmacy-ready presentations;
• reduced preparation time;
• improved dose accuracy;
• centralized pharmacy compounding;
• future combination-device development.

The liquid product would probably require a separate formulation and stability program. It could also create a new patent family with claims directed to concentration, buffer composition, surfactant level, container closure, and storage conditions.

What formulation patents could protect Ziihera?

Potentially valuable patent categories include the following:

Patent category	Example claim scope	Business value
Composition of matter	Zanidatamab sequence, variants, or engineered formats	Core biologic exclusivity
Formulation composition	Antibody with histidine, sucrose, polysorbate, or alternative excipients	Product-specific protection
Lyophilization	Freeze-drying cycle, cake properties, moisture, reconstitution performance	Manufacturing barrier
Liquid formulation	Concentrated antibody solution with defined pH and excipient ranges	Lifecycle extension
Container closure	Low-binding vial, stopper, syringe, or infusion container	Presentation protection
Stability	Defined storage period or degradation profile	Commercial differentiation
Administration	Infusion rate, premedication, dose, or dosing interval	Method-of-use protection
Combination therapy	Zanidatamab with chemotherapy, immunotherapy, or other HER2 agents	Indication expansion
Subcutaneous delivery	High-concentration formulation and delivery device	Administration convenience
Manufacturing	Cell culture, purification, viral clearance, or aggregation-control process	Supply-chain protection

The strongest formulation patents generally combine narrow chemical limitations with a demonstrated technical effect. Broad claims covering routine antibody excipients may face written-description, enablement, obviousness, or lack-of-novelty challenges.

What is the patent and exclusivity outlook for Ziihera?

Ziihera is regulated as a biologic, so its exclusivity profile differs from that of a conventional small molecule. The main protection layers are:

• the biologic’s composition-of-matter patents;
• formulation and drug-product patents;
• manufacturing patents;
• method-of-use patents;
• FDA regulatory exclusivity;
• orphan-drug exclusivity, if applicable;
• pediatric exclusivity, if granted.

The FDA label identifies zanidatamab-hrii as a bispecific antibody product, but patent expiry dates must be assessed from the relevant U.S. patent families, terminal disclaimers, patent-term adjustment, patent-term extension, and any litigation or settlement outcome. A reliable expiry table cannot be constructed from the label alone.

The product does not follow the conventional small-molecule Orange Book listing model. Reference-product and biosimilar competition are analyzed through the Purple Book, FDA biologics exclusivity rules, and the patent-information procedures under the Biologics Price Competition and Innovation Act.

For a biologic approved in 2024, FDA reference-product exclusivity generally provides 12 years from first licensure before a biosimilar may be licensed based on the abbreviated pathway, subject to statutory rules and product-specific issues.[4] That regulatory period is separate from patent protection and does not eliminate earlier patent litigation risk.

When does Ziihera lose exclusivity?

Regulatory exclusivity is not expected to expire before the early-to-mid 2030s based solely on the 12-year reference-product framework. Patent expiration could occur earlier or later depending on the relevant patent families.

A commercial exclusivity timeline is therefore best expressed as follows:

Event	Timing or status
FDA approval	November 2024
Reference-product biologic exclusivity	Statutory period generally extends to approximately 2036, subject to FDA determination
Pediatric exclusivity	Potential six-month extension if awarded
Composition patents	Must be assessed by patent family and granted claims
Formulation patents	May extend beyond core biologic claims if valid and enforceable
Biosimilar filing	Governed by the BPCIA and FDA biosimilar pathway
Biosimilar launch	Depends on litigation, settlement, patent expiry, and regulatory approval

Are Paragraph IV challenges relevant to Ziihera?

Traditional Paragraph IV certifications apply to patents listed in the Orange Book for small-molecule drugs. Ziihera is a biologic, so a biosimilar applicant would use the BPCIA patent-exchange and litigation framework rather than a conventional Paragraph IV certification.

A competing biologic could challenge:

• composition-of-matter patents;
• formulation patents;
• manufacturing patents;
• dosing patents;
• combination-treatment patents;
• patents covering specific HER2-positive cancer populations.

The practical risk is greatest where a patent estate contains multiple claim types that can support an injunction request or delayed launch. Method-of-use patents may be less effective if a biosimilar sponsor can obtain a non-infringing label through indication carve-outs.

What formulation opportunities exist for Ziihera?

Subcutaneous zanidatamab

Subcutaneous delivery is the most important potential commercial opportunity. A subcutaneous version could reduce infusion-center time and expand treatment into outpatient or community settings.

The technical challenge is dose volume. Ziihera uses weight-based dosing, and a 20 mg/kg dose may require a high antibody mass for larger patients. Development may require:

• a higher-concentration formulation;
• recombinant hyaluronidase;
• a dual-chamber or co-packaged presentation;
• an autoinjector or wearable injector;
• local-tolerability optimization;
• viscosity reduction;
• stability after device exposure.

A subcutaneous product could support new patents and provide a differentiated market position even after intravenous biosimilar competition begins.

Ready-to-use intravenous presentation

A pharmacy-ready liquid vial or premixed infusion bag could reduce preparation time. This opportunity is more practical in the near term than subcutaneous delivery because it preserves the established intravenous route.

Relevant claims could cover:

• antibody concentration;
• infusion-container compatibility;
• in-use stability;
• hold time after dilution;
• low-shear handling;
• particulate control;
• refrigerated or room-temperature storage.

Reduced-volume formulation

A higher-concentration product could reduce infusion volume and shorten administration time. It would also lower shipping volume and potentially reduce vial waste. The trade-off is increased viscosity and greater sensitivity to aggregation.

Dual-vial and dose-efficient packaging

Because the dose is weight-based, a 300 mg single-dose vial can create residual drug waste. Packaging options could include:

• 100 mg and 300 mg vial combinations;
• larger multi-dose formats, if microbiological and regulatory requirements permit;
• dose-banded presentation;
• pharmacy pooling under validated conditions;
• ready-to-use bags prepared by centralized facilities.

Packaging changes may not require a new active ingredient, but they can produce meaningful hospital-economics benefits.

What manufacturing and intellectual-property barriers affect Ziihera?

The principal manufacturing barriers are associated with antibody yield, product quality, aggregation control, bispecific assembly, purification, viral clearance, and analytical characterization.

Bispecific antibodies require more extensive analytical control than many conventional monoclonal antibodies. Developers must characterize:

• correct heavy-chain and light-chain pairing;
• mispaired species;
• charge variants;
• aggregates and fragments;
• glycosylation;
• potency across both HER2-binding arms;
• residual host-cell proteins and DNA;
• process-related impurities.

An excipient strategy that reduces aggregation or improves recovery can have direct manufacturing value. It may permit higher concentration, lower filtration loss, longer hold times, or fewer rejected batches.

The most defensible manufacturing patents are likely to claim a defined process linked to a measurable product attribute. Process claims that do not improve purity, yield, stability, or consistency have lower commercial leverage.

How does Ziihera compare with competing HER2 drugs?

Product	Modality	HER2 use	Administration	Excipient and lifecycle implications
Ziihera	Bispecific antibody	HER2-positive biliary tract cancer; broader development program	Intravenous every two weeks	Lyophilized product with opportunity for liquid or subcutaneous conversion
Herceptin	Monoclonal antibody	Multiple HER2-positive cancers	Intravenous and subcutaneous versions	Established subcutaneous benchmark and biosimilar competition
Enhertu	Antibody-drug conjugate	HER2-positive and HER2-low cancers	Intravenous	Payload-linked toxicity and formulation requirements differ from naked antibodies
Tukysa	Small-molecule HER2 tyrosine kinase inhibitor	HER2-positive breast and colorectal cancer	Oral	Orange Book and Paragraph IV framework applies
Kadcyla	Antibody-drug conjugate	HER2-positive breast cancer	Intravenous	Conjugation, payload, and drug-to-antibody-ratio controls create manufacturing barriers

Ziihera’s differentiation is the bispecific binding mechanism and its initial positioning in a disease area with limited HER2-directed options. Its formulation disadvantage is the need for intravenous preparation and infusion. A more convenient presentation could improve adoption without changing the underlying biology.

Which companies could challenge Ziihera commercially?

Potential competitive pressure can come from several directions:

• biosimilar developers targeting zanidatamab after regulatory and patent barriers decline;
• developers of other HER2 bispecific antibodies;
• antibody-drug conjugate companies expanding into biliary tract cancer;
• immunotherapy combinations;
• small-molecule HER2 inhibitors;
• diagnostic companies improving HER2 testing and patient selection.

The most credible near-term competitive threat is not necessarily a biosimilar. It is a competing HER2-directed regimen that gains first-line use, produces durable responses, or offers outpatient administration.

What licensing opportunities exist around Ziihera excipients?

Licensing opportunities are strongest in technologies that solve a defined product problem. Relevant targets include:

• high-concentration antibody stabilization;
• polysorbate-free formulations;
• low-binding container systems;
• lyophilization-cycle optimization;
• rapid reconstitution;
• subcutaneous delivery platforms;
• recombinant hyaluronidase;
• wearable infusion devices;
• pharmacy-ready admixture systems;
• analytical methods for bispecific aggregation and mispairing.

A transaction could take the form of an exclusive field license, regional license, co-development agreement, formulation-services agreement, or supply agreement. The commercial value depends on whether the technology is necessary for a new presentation or merely improves manufacturing cost.

What revenue exposure could formulation improvements create?

Ziihera’s revenue opportunity is linked to three variables: eligible HER2-positive patient volume, treatment duration, and expansion into earlier-line or additional tumor indications. Formulation improvements can affect all three indirectly by reducing treatment friction.

Commercial lever	Effect of improved formulation
Infusion-center capacity	More patients treated per site
Dose preparation	Lower pharmacy labor and product loss
Treatment adherence	Fewer delays and easier scheduling
Community oncology adoption	Broader site-of-care access
Subcutaneous conversion	Lower administration burden
Global distribution	Better stability and lower logistics cost
Biosimilar defense	New presentation patents and switching barriers
Pricing support	Potential justification for differentiated product presentation

Exact revenue estimates require public sales data, indication-specific market forecasts, treatment duration, dosing mix, and payer assumptions. The strategic conclusion is clear: a formulation that materially reduces administration time or drug waste could protect market share after the core biologic begins facing competition.

What is the FDA regulatory status of Ziihera formulation changes?

A formulation change may require a comparability package addressing:

• pharmacokinetics;
• immunogenicity;
• potency;
• aggregation;
• particles;
• degradation products;
• container compatibility;
• stability;
• in-use performance;
• clinical bridging, if comparability is not sufficient.

A liquid-to-lyophilized or intravenous-to-subcutaneous change would likely require more extensive development than a manufacturing-site transfer using the same formulation. The regulatory pathway would depend on the magnitude of the change and whether the new presentation is introduced as a supplement, a new strength, a new dosage form, or a separate biologic product.

Key Takeaways

• Ziihera is a 2024 FDA-approved bispecific antibody for previously treated HER2-positive biliary tract cancer.
• The commercial formulation uses histidine, histidine hydrochloride monohydrate, sucrose, and polysorbate 20 in a 300 mg lyophilized vial.
• The leading excipient opportunities are polysorbate reduction, improved lyophilization, liquid stability, higher concentration, and subcutaneous conversion.
• Ziihera is governed by biologic exclusivity and BPCIA procedures rather than the conventional Orange Book Paragraph IV system.
• A regulatory exclusivity period generally extends into approximately 2036, while patent expiry depends on the specific U.S. patent families.
• The most valuable lifecycle patents will likely cover high-concentration formulations, device-compatible presentations, subcutaneous delivery, and measurable stability or manufacturing improvements.
• Ready-to-use intravenous and subcutaneous products could reduce infusion-center burden and strengthen Ziihera against later biosimilar and HER2-directed competition.

FAQs About Ziihera Excipient and Commercial Strategy

Does Ziihera contain polysorbate 20?

Yes. Ziihera’s approved formulation includes polysorbate 20 as a surfactant to limit protein adsorption and aggregation during manufacturing, storage, reconstitution, and infusion.[1]

Is Ziihera a lyophilized antibody?

Yes. Ziihera is supplied as a lyophilized powder in a 300 mg single-dose vial and must be reconstituted before intravenous administration.[1]

Can a biosimilar company use the same Ziihera excipients?

A biosimilar may use the same or different excipients, provided the product meets applicable comparability, safety, quality, and regulatory requirements. Formulation patents could restrict commercial use even when the active antibody is otherwise eligible for biosimilar development.

Could Ziihera be converted to subcutaneous administration?

Potentially. A subcutaneous version would require higher concentration, injection-volume control, local-tolerability testing, device development, and a regulatory comparability strategy. The change could support new formulation and device patent claims.

Is Ziihera listed in the Orange Book?

No conventional Orange Book listing should be expected because Ziihera is a biologic. Its patent and biosimilar position are evaluated through the Purple Book, FDA biologic exclusivity rules, and BPCIA procedures.

References

1. U.S. Food and Drug Administration. (2024). Ziihera (zanidatamab-hrii) prescribing information.
2. U.S. Food and Drug Administration. (2024, November 20). FDA grants accelerated approval to zanidatamab-hrii for biliary tract cancer.
3. ClinicalTrials.gov. (2024). A study of zanidatamab in participants with HER2-positive biliary tract cancer. National Library of Medicine.
4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar biological products: Information for healthcare professionals.